H.C.
Two bulls weigh in believing short-term financing pressure on SGYP stock will lessen with the funding reveal.
BTIG’s Tim Chiang says Synergy has a “differentiated product” on its hands compared to the current winning market player: Ironwood/Allergan’s Linzess.
There’s a new FDA-approved IBS-C medication on the scene. Today, the U.
Canaccord’s John Newman finds SGYP’s Trulance commercial potential enticing down the line against its competitors.
Now that SGYP has won over FDA approval in a new indication (IBS-C), did the biotech company’s competitive edge just get sharper?
Wednesday could mark a turning point for Synergy investors.
Ahead of the fourth quarter showcase from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) anticipated March 7th, first comes a PDUFA date of FDA judgment for …
Nagging capital overhang moves us to sidelines, says Derek Archila.
